Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

NCT01188278 · clinicaltrials.gov ↗

COMPLETED

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Chronic-Phase (CML-CP)

Interventions

DRUG: Imatinib

Sponsor

Bristol-Myers Squibb